Cel-Sci Total Non-Operating Income/Expense 2010-2025 | CVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cel-Sci total non-operating income/expense from 2010 to 2025. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Cel-Sci Total Non-Operating Income/Expense 2010-2025 | CVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cel-Sci total non-operating income/expense from 2010 to 2025. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$220.6B
Amgen (AMGN)	$158.8B
Gilead Sciences (GILD)	$136.4B
Vertex Pharmaceuticals (VRTX)	$120.4B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$78.4B
CSL (CSLLY)	$76.6B
Regeneron Pharmaceuticals (REGN)	$61.3B
Alnylam Pharmaceuticals (ALNY)	$41.1B
Argenex SE (ARGX)	$34.2B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$19.7B
Insmed (INSM)	$18.6B
Illumina (ILMN)	$15.7B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$13B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Roivant Sciences (ROIV)	$7.7B
Repligen (RGEN)	$7.3B